VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Preclinical Data for Potential Anxiety Treatment

 

• VTGN CEO “even more excited about PH94B’s potential to change lives without the risky side effects and safety concerns of benzos”
• Study results suggest PH94B’s mechanism of action may not have benzodiazepine-like side effects, such as sedation, cognitive impairment or abuse liability
• Company making significant progress in preparing PH94B for launch of pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder

VistaGen Therapeutics (NASDAQ: VTGN) has reported new preclinical findings differentiating the mechanism of action of PH94B from that of benzodiazepines (https://ibn.fm/Al4ur). PH94B is an intranasal neuroactive steroid VistaGen is preparing for Phase 3 development as a potential acute rapid-onset treatment of anxiety in adults with social anxiety disorder. As a solution to anxiety notably lacking the notorious side effects of traditional medications, the formulation could be a game-changer to the world of mental health. 

“We are very pleased with the results of these studies that suggest PH94B’s mechanism of action may not have benzodiazepine-like side effects, such as sedation and cognitive impairment, or abuse liability,” said VistaGen CEO Shawn K. Singh. “While benzodiazepines provide relief for many Americans struggling with anxiety, the extremely risky safety profile does not lend itself to long-term use. The mechanism of action contributes to the safety profile.”

VistaGen, a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, reported that new in vitro electrophysiology data demonstrating that PH94B’s mechanism of action does not involve direct activation of GABA-A receptors. That is in direct contrast to the mechanism of action of benzodiazepines (benzos), which act as direct positive modulators of GABA-A receptors.

“As we have seen in Phase 2 clinical studies, while PH94B is able to produce rapid-onset benzo-like, anti-anxiety effects, this study demonstrates that PH94B does not have a benzo-like mechanism of action,” noted Singh. “As we approach Phase 3 development of PH94B, especially given the FDA’s recent public announcement about safety concerns associated with benzo use, these new data make us even more excited about PH94B’s potential to change lives without the risky side effects and safety concerns of benzos.”

In additional news, VistaGen also provided business updates and released its financial results for the fiscal 2021 second quarter ended September 30, 2020 (https://ibn.fm/kBQkL). Key highlights for the company included a positive FDA meeting that outlined the pathway to a key PH94B Phase 3 study beginning recruitment Q2 2021, along with news that the company had received more than $17.5 million in net proceeds from a public offering of common stock and a PH94B upfront license payment. The company also noted positive new data had been gathered from its second preclinical study of AV-101 in combination with probenecid.

“We see a significant rise in mental health concerns as the global COVID-19 pandemic continues to impact the daily lives of millions of individuals,” observed Singh. “We are committed to developing innovative therapies that provide relief to those suffering from anxiety and depression, and we are working diligently towards that goal.

“We are making significant progress in preparing PH94B for launch of a pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder in the second quarter of 2021,” he continued. “After reaching consensus with the FDA on the key components of the study design, it will be very similar to the statistically significant Phase 2 study of PH94B in social anxiety disorder. We are also working with the FDA to finalize details for our Phase 2A study of PH94B in adjustment disorder, which we are planning to initiate in early 2021.”

VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date and therapeutic potential in multiple CNS markets.

For more information, visit the company’s website at www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

As World Transitions away from Gas Guzzlers, Net Element Inc. (NASDAQ: NETE) Entering EV Market Through Mullen Technologies Merger

 

• NETE plans to divest payments processing model to enter EV industry through proposed merger with privately-held Mullen Technologies Inc.
• Merger allows Mullen stakeholders to obtain majority of stock while accelerating process of taking company public, funding US expansion
• Mullen accepting reservations for Dragonfly K50 sports car and MX-05 SUV, production for both projected to start in 2021
• California-based Mullen subsidiaries include Mullen Energy, Mullen Auto Sales, Mullen Finance Corp., CarHub digital marketplace

Future generations may look back and wonder how humanity withstood the exhaust fumes, noise and environmental degradation created by fossil fuel engines. The downsides of combustible engines, rising fuel prices and positive government incentives are all factors driving EVs into the mainstream – and some experts predict purely electric models will surpass hybrids during the transition. Net Element (NASDAQ: NETE), through its proposed merger with Mullen Technologies, is planning to divest its payments processing business model to enter the burgeoning EV industry. The strategic move will allow the stakeholders of privately held Mullen to gain a majority of the new stock while catalyzing the process of taking the company public and accelerating its expansion in the United States.

The bold move comes at a time of rapid industry expansion amid growing concern for the environment among the general public and policy-makers. Falling battery prices, government mandates and consumer incentives are propelling the industry forward, prompting some industry experts to predict that the pure electric models will surpass hybrids within the next few years as the transition takes place.

“I think we’ll see a faster transition to pure EVs,” said Dane Parker, an industry executive and participant at Business Insider’s IGNITION: Transportation virtual event (https://ibn.fm/cJ470). Besides his belief that hybrids are more complex to engineer, Parker predicts that by 2025 battery prices will have dropped substantially, resulting in the accelerated adoption of pure electric vehicles and their eventual dominance over hybrids.

Through its subsidiaries that include Mullen Auto Sales, Mullen Finance Corp., a digital marketplace called CarHub and battery-focused Mullen Energy, Mullen Technologies has already made significant headway in the US. Among the company’s expansion plans is the production of the Dragonfly K50 luxury electric sports car at its new proposed 1.3 million square-foot assembly and manufacturing space in Spokane, Washington. Featuring a Rechargeable Energy Storage System (RESS), the Dragonfly boasts a range of up to 310 miles and can accelerate from 0-60 miles/hour in under 4.2 seconds. Limited to only 1000 units, the company has started accepting reservations with production set to begin next year.

Pre-orders for another Mullen vehicle – the five-passenger MX-05 – have also begun. Production for the pure electric all-wheel SUV is set to begin in 2021 with deliveries set for mid-2022. Starting at $55,000, the MX-05 boasts a range of 325 miles on a single charge and can hit 60 miles/hour from zero in just 3.2 seconds.

Formerly a global financial technology and value-added solutions group, NETE plans to leverage the increased demand for electric vehicles through a proposed merger with Mullen Technologies. Based in California, Mullen Technologies engages in electric vehicle manufacturing across an international distribution network, partnering with several original equipment manufacturers across the world to provide exciting EV options for the US market.

For more information, visit the company’s website at www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Featured in SNN Network Interview

 Jupiter Wellness (NASDAQ: JUPW), a leading developer of cannabidiol (“CBD”) based therapeutics and wellness products, today announced that it was featured in a new video interview with SNN Network, “The Official Small-, Micro- and Nano-Cap News Source(TM).” According to the update, Jupiter Wellness CEO Brian John and chairman and Chief Scientific Officer Dr. Glynn Wilson joined SNN host Robert Kraft to discuss the company’s focus on proprietary patent/patent-pending CBD sun and skin care brands. “We wanted to focus this company on our own proprietary patented or patent-pending products, and that’s really what Jupiter Wellness was built around. We have four very significant patent/patent-pending treatments in skin health . . . one for eczema, one for burns, one for herpes and one for skin cancer,” John said in the interview.

To view the full press release, visit https://ibn.fm/CdhHb

About Jupiter Wellness Inc.

Jupiter Wellness is a leading developer of cannabidiol (“CBD”) based medical therapeutics and wellness products. The company’s clinical pipeline of prescription CBD-enhanced skin care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenues from a growing line of proprietary over-the-counter skincare products including its flagship CaniSun(TM) sunscreen and other wellness brands sold through its robust distribution platform. For more information, visit the company’s website at www.JupiterWellnessInc.com.

NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW 

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Advancement of MS1819 Combination Therapy Trial in Turkey

 AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the first two patients have been dosed in Turkey for its Phase 2 trial. The trial evaluates its investigational drug, MS1819, in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (“PERT”), for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). “In the midst of a global pandemic and unpredictable obstacles, we are very encouraged to see our combination therapy trial moving forward at one of the clinical testing sites in Turkey,” said James Sapirstein, president & CEO of AzurRx. “We expect to release topline results in the second quarter of next year. We are optimistic the results will build on the encouraging data we received earlier this year and hope we will be one step closer to improving the lives of thousands of patients suffering from cystic fibrosis.”

To view the full press release, visit https://ibn.fm/QTN6c

About AzurRx BioPharma Inc.

AzurRx BioPharma is a biopharmaceutical company specialized in the research and development of non-systemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Wrap Technologies Inc. (NASDAQ: WRTC) to Begin Trading Under Nasdaq Ticker Symbol “WRAP”

 Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, today announced that its Nasdaq ticker symbol is set to change from “WRTC” to “WRAP” beginning at market open on Tuesday, December 1, 2020. “We are excited to align the new ticker symbol ‘WRAP’ directly to our corporate brand and strengthen our visibility with public investors while providing consistent brand recognition across all stakeholders,” Wrap Technologies President and Interim CEO Tom Smith stated in the news release. “We are protecting our WRAP(R) and BolaWrap(R) brands in 50 countries as our brand recognition continues to increase worldwide. The recent change of our corporate web site to ‘wrap.com’ along with the new ticker symbol makes it easier for customers, current shareholders and prospective investors to find and follow our company.”

To view the full press release, visit https://ibn.fm/WjO3T

About Wrap Technologies Inc.

WRAP Technologies, Inc. is an innovator of modern policing solutions. The company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a distance from 10 to 25 feet. Developed by award winning inventor Elwood Norris, the Company’s Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement in safely and effectively deescalating encounters, especially those involving an individual in crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury in a number of cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, and Oak Ridge. For information, visit the company’s website at www.WrapTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to WRTC are available in the company’s newsroom at http://ibn.fm/WRTC

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Trxade Group Inc.’s (NASDAQ: MEDS) Platform Meets Today’s Demands Through Intelligent Design

 Trxade Group NASDAQ: MEDS), an integrated drug-procurement, delivery and health care platform, is ideally situated as the global pandemic has led to a cascade of changes involving how health care is administered, perhaps most notably in the increased adoption of telehealth services. Trxade Group’s business model appears to aptly and effectively meet today’s demands, largely demonstrated by the company’s revenue growth that has far exceeded expectations. A recent article discusses intelligent design of the Trxade platform that meets current standards of care while prioritizing information flow to assist both patients and providers. The article reads, “The company’s artificial intelligence API is designed to streamline the transfer of information between health care industry businesses. Trxade’s model thereby helps smaller, independent pharmacies in particular to competitively serve patients in spite of the proliferation of large pharmaceutical chains.”

To view the full article, visit https://ibn.fm/JfIvU

About Trxade Group Inc.

Headquartered in Tampa, Florida, Trxade Group is an integrated drug-procurement, delivery and health care platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making health care services affordable and accessible. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms: (1) the Trxade B2B trading platform with 11,725 registered pharmacies; (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division; (3) the Bonum Health platform offering affordable telehealth services; and (4) the DelivMeds app, which coordinates a nationwide distribution network through independent pharmacies or mail-order delivery. For additional information, please visit www.Trxade.com, www.DelivMeds.com and www.BonumHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) to Provide Digital Therapeutics Solution to Employees of Fortune 500 Company

 DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, will be providing its digital therapeutics solution to qualified employees of a U.S.-based Fortune 500 technology company. The contract, which goes into effect on Jan. 1, 2021, with the beginning of a new benefits year, calls for Dario to provide its digital diabetes tools and coaching to employees and their dependents. “We believe that employees will benefit from Dario’s unique therapeutic approach, which delivers adaptive, personalized experiences designed to drive behavior change through intuitive, clinically proven digital tools and coaching,” said DarioHealth president and North America GM Rick Anderson in the press release. “These employees will join a community of tens of thousands of members who engage with Dario every day to measurably improve their health. This contract was awarded through a request for proposal (“RFP”) process that included Dario’s largest competitors, and we believe it represents an important milestone in our strategic shift toward the business-to-business-to-consumer (“B2B2C”) market comprised of self-insured employers, healthcare provider networks, and insurance plans. We believe this further validates the competitive strength of our top-rated digital chronic care solution and will serve as an important market reference in converting our employer pipeline.”

To view the full press release, visit https://ibn.fm/KV3gi

About DarioHealth Corp.

DarioHealth Corp. is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Dario’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html